Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 736 to 750 of 2548 results for methods

  1. Port Delivery platform with ranibizumab for treating wet age-related macular degeneration [ID3983]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 8 January 2026.

    Technology appraisal guidance
    In consultation

  2. Port Delivery platform with ranibizumab for treating wet age-related macular degeneration [ID3983]

    Awaiting development Reference number: GID-TA10879 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]

    In development Reference number: GID-TA11651 Expected publication date:  04 June 2026

    Technology appraisal guidance
    In development

  4. Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]

    In development Reference number: GID-TA11572 Expected publication date:  25 February 2026

    Technology appraisal guidance
    In development

  5. Bair Hugger for measuring core temperature during perioperative care (MIB99)

    NICE has developed a medtech innovation briefing (MIB) on Bair Hugger for measuring core temperature during perioperative care .

    Medtech innovation briefing
    Published
    28 March 2017

  6. Rimegepant for preventing migraine (TA906)

    Evidence-based recommendations on rimegepant (Vydura) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    5 July 2023
    View recommendations

    Sections for TA906

  7. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]

    In development Reference number: GID-HST10063 Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  8. Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379

    In development Reference number: GID-TA11429 Expected publication date:  25 September 2026

    Technology appraisal guidance
    In development

  9. Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]

    Awaiting development Reference number: GID-TA11019 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. DCVax-L for treating glioblastoma [ID836]

    In development Reference number: GID-TA10143 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]

    In development Reference number: GID-TA10990 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (TA86)

    Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.

    Technology appraisal guidance
    Last updated
    1 November 2010
    View recommendations

    Sections for TA86

  13. Arctic Sun 5000 for therapeutic hypothermia after cardiac arrest (MIB112)

    NICE has developed a medtech innovation briefing (MIB) on Arctic Sun 5000 for therapeutic hypothermia after cardiac arrest .

    Medtech innovation briefing
    Published
    18 July 2017

  14. Further research into the analytical and clinical validity of the enzyme-linked immunosorbent assay (ELISA) kits (LISA-TRACKER, IDKmonitor and Promonitor) is recommended, specifically on:- the best methods to measure tumour necrosis factor (TNF)-alpha-inhibitor levels in the presence of antibodies to TNF-alpha inhibitors- developing primary reference standards- the accuracy for predicting clinical state- clinically meaningful thresholds.

    IDKmonitor and Promonitor) is recommended, specifically on:- the best methods to measure tumour necrosis factor (TNF)-alpha-inhibitor...

    Research recommendation
    Published
    21 March 2016

  15. Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495]

    In development Reference number: GID-TA11638 Expected publication date: TBC

    Technology appraisal guidance
    In development